NCT07125261View on ClinicalTrials.gov

BHV-7000 Responsive Neurostimulation System (RNS) Study

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

September 30, 2026

Conditions
EpilepsySeizures
Interventions
DRUG

BHV-700

75 mg daily for the 4-week treatment period (dose which may be adjusted based on tolerability)

Trial Locations (1)

06520

Yale Comprehensive Epilepsy Center, New Haven

Sponsors
All Listed Sponsors
collaborator

Biohaven Pharmaceuticals, Inc.

INDUSTRY

lead

Yale University

OTHER